LUPUS RESEARCH ALLIANCE INC
LUPUS RESEARCH ALLIANCE INC
LUPUS RESEARCH ALLIANCE INC
Programs
Lupus Research Funding Initiatives
THE LUPUS RESEARCH ALLIANCE (LRA), THE LARGEST NON-GOVERNMENTAL, PRIVATE FUNDER OF LUPUS RESEARCH WORLDWIDE: FUNDS INNOVATIVE RESEARCH THAT SPANS THE SPECTRUM FROM FOUNDATIONAL TO CLINICAL RESEARCH. FOSTERS DIVERSE SCIENTIFIC TALENT, STIMULATES COLLABORATIONS, AND DRIVES DISCOVERIES TO TRANSFORM TREATMENT WHILE ADVANCING TOWARD A CURE. HAS INVESTED NEARLY $272 MILLION IN LUPUS RESEARCH INCLUDING 620+ RESEARCH GRANTS LRA-FUNDED RESEARCH PAVED THE WAY FOR THE ONLY TWO BIOLOGIC DRUGS CURRENTLY APPROVED FOR LUPUS, AND THE LRA IS INVOLVED IN NUMEROUS ONGOING PHASE 3 TRIALS. FURTHER, LRA RESEARCH INVESTMENTS HAVE CONTRIBUTED TO THE IDENTIFICATION OR FURTHER VALIDATION OF TWO DOZEN DISEASE PATHWAYS IN LUPUS AND HAVE ENABLED THE DISCOVERY, PROOF OF CONCEPT, OR DEVELOPMENT OF MORE THAN A DOZEN DIFFERENT NEW THERAPIES FOR LUPUS. SINCE THE FORMATION OF THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN), LRA HAS DEDICATED $34 MILLION TO BOLSTER LUPUS CLINICAL RESEARCH INFRASTRUCTURE AND QUALITY.THE ORGANIZATION'S RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD INCLUDES TOP SCIENTIFIC EXPERTS, AND KEY LAY MEMBERS OF THE LRA'S BOARD OF DIRECTORS, WHO WORK WITH STAFF TO STRATEGICALLY GUIDE AND DRIVE THE RESEARCH FUNDING AGENDA.IN 2024 ALONE, OVER $12 MILLION WAS AWARDED IN GRANTS FOR 38 HIGHLY INNOVATIVE PROJECTS WITH THE POTENTIAL TO IMPROVE TREATMENT AS WELL AS UNDERSTAND THE CAUSES OF LUPUS AND THUS LEAD TO A CURE. BELOW IS A SUMMARY OF RESEARCH GRANTS AND PROGRAMS FUNDED BY THE LRA IN 2024: 1) 11 LUPUS INNOVATION AWARD GRANTS WERE AWARDED TOTALING ALMOST $4 MILLION OVER TWO YEARS, THIS PROGRAM SUPPORTS PIONEERING, HIGH-RISK, HIGH-REWARD PROJECTS ADDRESSING MAJOR CHALLENGES IN LUPUS RESEARCH. EARLY-STAGE INVESTIGATORS ARE GIVEN SPECIAL CONSIDERATION DURING THE REVIEW PROCESS AND ARE ELIGIBLE FOR A THIRD YEAR OF FUNDING; 2) 6 ADMINISTRATIVE LUPUS RESEARCH SUPPLEMENT GRANTS WERE AWARDED TOTALING $90,000. THIS PROGRAM SUPPORTS PROMISING TRAINEES WHO ARE WORKING WITH LRA-FUNDED RESEARCHERS OR INVESTIGATORS FOCUSED ON AUTOIMMUNITY SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH (NIH), DEPARTMENT OF DEFENSE (DOD), OR EQUIVALENT GRANTS IN GOOD STANDING. 3) 3 GRANTS TOTALING APPROXIMATELY $1.8 MILLION WERE AWARDED TO RESEARCHERS IN THE CAREER DEVELOPMENT AWARD PROGRAM THAT AIMS TO SUPPORT EARLY CAREER INVESTIGATORS FOR THE PERIOD BETWEEN THE COMPLETION OF POST-DOCTORATE FELLOWSHIP TRAINING AND ESTABLISHMENT AS AN INDEPENDENT INVESTIGATOR. THE PROGRAM PROVIDES UP TO $600,000 OVER FOUR YEARS. 4) 2 POSTDOCTORAL GRANTS FELLOWSHIP GRANTS AWARDED, THIS GRANT IS DESIGNED TO FUND PROMISING RESEARCH FELLOWS AND PROVIDES THEM WITH UP TO $170,000 OVER TWO YEARS TO SUPPORT THE GENERATION OF DATA, UNIQUE RESEARCH IDEAS AND PROGRESS TO TRANSITION TO AN INDEPENDENT RESEARCH ROLES FOCUSED ON LUPUS RESEARCH. 5) 5 TRANSLATIONAL BRIDGE AWARDS FUNDED TOTALING APPROXIMATELY $2.2 MILLION. THIS PROGRAM PROVIDES UP TO $450,000 OVER TWO YEARS, WITH A GOAL TO BRIDGE THE GAP BETWEEN POST-DISCOVERY AND PRE-COMMERCIAL DEVELOPMENT WITH AN AIM TO ACCELERATE THE PACE AT WHICH PROMISING LRA-FUNDED FOUNDATIONAL RESEARCH DISCOVERIES ARE TRANSLATED INTO CLINICAL EVALUATION AND TRANSITIONED TO A VIABLE PRODUCT THAT WILL IMPACT PATIENTS DIRECTLY. 6) 11 TARGETED RESEARCH PROGRAM ON ENGINEERED CELL THERAPIES FOR LUPUS GRANTS TOTALING OVER $4 MILLION. THIS PROGRAM ADVANCES THE DEVELOPMENT OF NEXT GENERATION ENGINEERED CELL THERAPIES WITH A CLEAR AND DIRECT RELEVANCE TO PEOPLE WITH LUPUS.7) THE LUPUS INSIGHT PRIZE WAS AWARDED $200,000. THIS AWARD RECOGNIZED TWO LEADING RESEARCHERS WHO HAVE MADE A MAJOR CONTRIBUTION RELEVANT TO LUPUS, AS PART THE LRA'S COMMITMENT TO COLLABORATION, THE LRA WORKS WITH A VARIETY OF PARTNERS ACROSS SECTORS AIMED AT ACCELERATING RESEARCH DISCOVERIES, LEVERAGING RESOURCES, AND EXPEDITING THE DRUG DEVELOPMENT PROCESS TO IMPROVE THE QUALITY OF LIFE OF PEOPLE LIVING WITH LUPUS BRINGING TOGETHER THE KEY PLAYERS IN THE FIGHT AGAINST LUPUS -- OUR GRANTEES, SCIENTIFIC ADVISORS, CLINICIANS, THE BIOPHARMACEUTICAL INDUSTRY, THE U.S. GOVERNMENT, AND PEOPLE LIVING WITH LUPUS. THE LRA'S ROBUST FUNDING MODEL SUPPORTS PROMISING RESEARCH EFFORTS WITH THE GOAL OF IMPROVING THE LIVES OF PEOPLE WITH LUPUS SOON. THROUGH COMPETITIVE PEER-REVIEW PROCESS PROJECTS BY THE LRA AIM TO TRANSLATE RESULTS FROM THE RESEARCH BENCH TO THE BEDSIDE AS QUICKLY AS POSSIBLE. BECAUSE THE LUPUS RESEARCH ALLIANCE'S BOARD OF DIRECTORS FUNDS THE ADMINISTRATIVE AND FUNDRAISING EXPENSES, 100% OF ALL OTHER CONTRIBUTIONS GOES TO SUPPORT THE LRA'S LUPUS RESEARCH PROGRAMS.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$14.6MInnovative Lupus Research Initiatives
THE LUPUS RESEARCH ALLIANCE (LRA) HAS MADE SIGNIFICANT STRIDES IN ADVANCING ITS SCIENTIFIC MISSION THROUGH STRATEGIC PLANNING, PROGRAM EXPANSION AND OPERATIONAL IMPROVEMENTS.IN 2024, THE LRA SUCCESSFULLY DEVELOPED AND IMPLEMENTED THE FIRST-YEAR GOALS OF ITS 20242028 RESEARCH STRATEGY. IN ALIGNMENT WITH THE UPDATED RESEARCH STRATEGY, LRA LAUNCHED SEVERAL INNOVATIVE, PATIENT-CENTRIC RESEARCH INITIATIVES, INCLUDING THE TRANSLATIONAL BRIDGE AWARD, THE TARGETED RESEARCH PROGRAM ON ENGINEERED CELL THERAPIES, THE RENEWED CYCLE OF THE COMMON MECHANISMS IN AUTOIMMUNE DISEASES PROGRAM, AND THE MECHANISTIC CLINICAL STUDIES AWARD. ADDITIONALLY, THE ORGANIZATION BEGAN DEVELOPING A LUPUS BIOMARKERS STRATEGY AND INITIATED THE DEVELOPMENT OF A COMPREHENSIVE DATA STRATEGY, SCHEDULED FOR COMPLETION IN 2025.LRA'S CURRENT GRANT PROGRAMS, INCLUDING THE GLOBAL TEAM SCIENCE AWARD (GTSA), CAREER DEVELOPMENT AWARD, POST DOCTORAL AWARD, AND LUPUS INNOVATION AWARD --WERE EXPANDED AND OPTIMIZED THROUGH ACTIVE STAFF OVERSIGHT AND STRATEGIC COLLABORATIONS. THIS INCLUDED LAUNCHING A REQUEST FOR APPLICATIONS IN A COLLABORATIVE PROGRAM ACROSS THE GTSA AND CONTINUING THE ADMINISTRATIVE SUPPLEMENT TRAINING PROGRAM.TO RAISE THE VISIBILITY OF ITS RESEARCH PROGRAMS, LRA SUBMITTED MULTIPLE ABSTRACTS TO INTERNATIONAL SCIENTIFIC MEETINGS, SEVERAL WERE ACCEPTED AND WILL BE PRESENTED IN 2025. THE ORGANIZATION ALSO HOSTED A SUCCESSFUL AND ENGAGING ANNUAL INVESTIGATOR'S AND PROGRAM SPECIFIC MEETINGS: FORUM FOR DISCOVERY, ALLIANCE OF GTSA AND OTHER PROGRAM-SPECIFIC RESEARCH MEETINGS IN NOVEMBER OF 2024. OPERATIONAL IMPROVEMENTS INCLUDED THE SELECTION AND IMPLEMENTATION OF A NEW GRANT MANAGEMENT SYSTEM, THE RECRUITMENT AND ONBOARDING OF TWO STAFF SCIENTISTS AND A LUPUS ABC ADMINISTRATOR, AND THE STRENGTHENING OF THE RESEARCH TEAM THROUGH TARGETED TEAM-BUILDING AND PROFESSIONAL DEVELOPMENT EFFORTS. LUPUS ABC HAS BEEN SUCCESSFULLY ESTABLISHED AS A MODEL PUBLIC-PRIVATE PARTNERSHIP IN THE REGULATORY SPACE, DEMONSTRATING LEADERSHIP AND INNOVATION IN ADVANCING LUPUS RESEARCH AND EXPERIENCED SUBSTANTIAL GROWTH IN MEMBERSHIP DURING 2024. THE INITIATIVE SECURED ACTIVE PARTICIPATION FROM THE FDA'S CENTER FOR BIOLOGICS EVALUATION AND RESEARCH, REINFORCING ITS CREDIBILITY AND COLLABORATIVE STRENGTH. A MAJOR MILESTONE WAS THE FDA'S ACKNOWLEDGMENT OF CLASI 70 AS A PRIMARY EFFICACY ENDPOINT IN CUTANEOUS LUPUS CLINICAL TRIALS, MARKING A SIGNIFICANT ADVANCEMENT IN CLINICAL OUTCOME MEASUREMENT. ADDITIONALLY, LUPUS ABC CONVENED A DEDICATED PATIENT-REPORTED OUTCOMES (PRO) MEETING TO FURTHER INTEGRATE PATIENT PERSPECTIVES INTO RESEARCH AND REGULATORY STRATEGIES. LUPUS NEXUS COMPLETED ITS INFRASTRUCTURE BUILD AND OFFICIALLY LAUNCHED TO BOTH RESEARCH AND PATIENT COMMUNITIES. IT FINALIZED FOUNDATIONAL ANALYSIS PLANS, SELECTED KEY VENDORS, AND RECRUITED 200 PARTICIPANTS. ADDITIONALLY, 10 NEW CLINICAL SITES WERE ACTIVATED THROUGH LUCIN (SEE BELOW), AND A SUSTAINABLE FINANCIAL MODEL WITH A DEFINED MEMBERSHIP FEE STRUCTURE WAS ESTABLISHED. LUPUS THERAPEUTICS, LLC :THE LRA FOUNDED LUPUS THERAPEUTICS, LLC (LT) AS THE CLINICAL RESEARCH AFFILIATE OF THE LRA IN 2018. WITH THIS ADDITION, THE LRA IS THE ONLY ORGANIZATION LEADING LUPUS RESEARCH ACROSS THE CONTINUUM FROM ACCELERATING BASIC DISCOVERIES IN THE LAB THROUGH CLINICAL EVALUATION OF NEW THERAPIES. MANY OF THE BASIC RESEARCH BREAKTHROUGHS SUPPORTED BY THE LRA HAVE HELPED UNRAVEL THE COMPLEXITIES OF LUPUS AND ENABLED THE DEVELOPMENT OF POTENTIAL TREATMENTS AND DIAGNOSTICS NOW IN CLINICAL STUDIES. LT IS ACTIVELY SUPPORTING SEVERAL CLINICAL STUDIES FOR NEW THERAPIES THROUGH THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN). LT OVERSEES LUCIN, A NORTH AMERICA-BASED LUPUS CLINICAL TRIALS NETWORK OF 60+ PREMIER RESEARCH MEDICAL CENTERS. THE LRA PROVIDED OVER $2.6 MILLION IN GRANTS IN 2024 TO CONTINUE FUNDING TOP ACADEMIC CENTERS TO FOSTER ROBUST, HIGH QUALITY CLINICAL TRIAL CONDUCT WITH PARTICIPATION ACROSS NORTH AMERICA.LT ALSO OFFERS EXPERTISE COMBINED WITH THAT OF 250+ LUCIN PROVIDERS AND THE LRA TO SUPPORT ACADEMIC, NONPROFIT AND BIOTECH AND PHARMACEUTICAL ORGANIZATIONS TO PLAN, INITIATE AND MANAGE CLINICAL RESEARCH. THIS OCCURS THROUGH DIVERSE ADVISORY SERVICES AND DIRECT CLINICAL OPERATIONS SUPPORT. AN ANNUAL LUCIN COMMUNITY MEETING IS HELD TO BRING TOGETHER ALL OF THE PARTNERS IN CLINICAL RESEARCH TO HIGHLIGHT RECENT ADVANCEMENTS, BOLSTER UNDERSTANDING, ADDRESS CURRENT CHALLENGES IN CLINICAL RESEARCH AND ENCOURAGE COLLABORATION FOR SUCCESSFUL DEVELOPMENT OF NEW TREATMENT APPROACHES.IN ADDITION, LT HAS EXPANDED THE FIRST PEER-TO-PEER CLINICAL TRIALS EDUCATION PROGRAM, PATIENT ADVOCATES FOR LUPUS STUDIES OR PALS TO INCLUDE TRIAL BUDDY SUPPORT DURING PARTICIPATION IN CLINICAL TRIALS. PALS AIMS TO IMPROVE CLINICAL RESEARCH AWARENESS, KNOWLEDGE AND ENROLLMENT, WITH A SPECIFIC FOCUS ON MAKING SURE POPULATIONS AT GREATEST RISK FOR LUPUS ARE WELL REPRESENTED IN STUDIES. LT ALSO SUPPORTS OTHER PATIENT ENGAGEMENT ACTIVITIES SUCH AS PATIENT ADVISORY BOARDS, PATIENT VISITS AND PATIENT PROTOCOL REVIEW COMMITTEES TO ENSURE THAT INDIVIDUALS IMPACTED BY LUPUS HAVE A VOICE IN THE TREATMENT DEVELOPMENT PROCESS. FINALLY, LT EFFORTS SUPPORT VARIOUS EDUCATION OFFERINGS FOR PROVIDERS AND PATIENTS, AND COMMUNITY-BASED OUTREACH TO ENSURE REPRESENTATIVE PARTICIPATION OF THE ENTIRE LUPUS COMMUNITY IN CLINICAL RESEARCH.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$14.8MLupus Advocacy and Public Policy Efforts
THE LUPUS RESEARCH ALLIANCE'S ADVOCACY EFFORTS FOCUS ON EDUCATING CONGRESS ABOUT LUPUS AND URGING CONGRESS AND THE ADMINISTRATION TO PROVIDE THE FUNDS AND SUPPORT NEEDED TO ADVANCE LUPUS RESEARCH THAT CAN LEAD TO BETTER TREATMENTS AND, ULTIMATELY, A CURE. EFFORTS ALSO INCLUDE WAYS TO ENSURE INCREASED DIVERSITY IN CLINICAL TRIALS AND REDUCING BARRIERS TO ENROLLMENT FOR ALL WHO WANT TO PARTICIPATE. THE TOP GOALS OF THE LUPUS RESEARCH ALLIANCE PUBLIC POLICY PROGRAM FOCUS MAINLY ON FUNDING FOR LUPUS RESEARCH THAT WILL LEAD TO BETTER TREATMENTS AND ELIMINATE RACIAL DISPARITIES IN HEALTHCARE. GOALS INCLUDE: INCREASING FEDERAL FUNDING FOR LUPUS RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH (NIH), AND SPECIFICALLY THE NATIONAL INSTITUTE FOR ALLERGY & INFECTIONS DISEASE (NIAID) AND NATIONAL INSTITUTE FOR ARTHRITIS & MUSCULOSKELETAL DISORDERS (NIAMS). ADDITIONALLY, LRA ADVOCATES FOR LUPUS RESEARCH THROUGH THE DEPARTMENT OF DEFENSE (DOD); SUPPORTING THE LRA'S PARTNERSHIP WITH THE FDA, THE LUPUS ACCELERATING BREAKTHROUGHS CONSORTIUM (LUPUS ABC); AND ENSURING THE PATIENT VOICE IS INCORPORATED IN THE DRUG DEVELOPMENT PROCESS. VOLUNTEERS ACROSS THE COUNTRY HELP AMPLIFY THESE OUTREACH EFFORTS.THROUGH THE LUPUS RESEARCH ALLIANCE ONGOING PUBLIC POLICY PROGRAM EFFORTS, SIGNIFICANT FUNDING FOR LUPUS RESEARCH HAS BEEN OBTAINED UNDER THE DEPARTMENT OF DEFENSE (DOD) CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS (CDMRP) OPERATED BY THE ARMY MEDICAL RESEARCH AND MATERIEL COMMAND. GIVEN THE HIGH DEMAND FOR NEW RESEARCH ALONGSIDE THE RISING NUMBERS OF WOMEN TREATED AT MILITARY HEALTH FACILITIES AS WELL AS THE LINK BETWEEN POST-TRAUMATIC STRESS DISORDER (PTSD) AND THE DEVELOPMENT OF AN AUTOIMMUNEDISEASE, THE LUPUS RESEARCH ALLIANCE HAS WORKED TO CONVINCE CONGRESS TO INCREASE ITS INVESTMENT AND PROVIDE $15 MILLION FOR THE LUPUS RESEARCH PROGRAM IN THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS OPERATED UNDER THE DEFENSE HEALTH PROGRAM IN THE DEFENSE APPROPRIATIONS BILL. THIS ADDITIONAL INVESTMENT IS CRITICAL FOR DISCOVERIES THAT CAN MAKE A DIFFERENCE IN PATIENTS' ABILITY TO BE THE BEST VERSION OF THEMSELVES. THE LRA LED THE PUSH FOR THE CREATION OF THE LUPUS RESEARCH PROGRAM, WHICH WAS FIRST FUNDED WITH $5 MILLION IN 2017 AND INCREASED TO $10 MILLION PER YEAR IN 2020. LRA LEADERSHIP, OUR ADVOCATES, AND ALLIED MEMBERS OF CONGRESS ARE WORKING TO ADVANCE RESEARCH PRIORITIES LIKE THIS THAT ARE CRITICAL TO THE LUPUS RESEARCH ALLIANCE AND ALL PEOPLE IMPACTED BY LUPUS.IN 2024, AS THE THREAT OF CUTS TO HEALTH RESEARCH FUNDING BECAME MORE PRONOUNCED, THE LUPUS RESEARCH ALLIANCE INTENSIFIED ITS ADVOCACY TO PROTECT AND EXPAND SUPPORT FOR LUPUS RESEARCH. LRA'S PRIMARY ADVOCACY PUSH CENTERED ON ENCOURAGING CONSTITUENTS TO ENGAGE WITH THEIR HOUSE LEGISLATORS DURING THE AUGUST CONGRESSIONAL RECESS. TO SUPPORT THIS EFFORT, LRA LAUNCHED A WEBPAGE WITH RESOURCES TO HELP ADVOCATES LOCATE THEIR LEGISLATORS AND IDENTIFY LOCAL TOWN HALLS AND EVENTS. ADDITIONALLY, STAFF HELD A VIRTUAL OFFICE HOUR SESSION TO ANSWER QUESTIONS AND HELP ADVOCATES PREPARE TO SHARE THEIR STORIES AND EMPHASIZE THE IMPORTANCE OF RESEARCH FUNDING.ONGOING ADVOCACY FOCUSES ON ENSURING LEGISLATION THAT SECURES THE FEDERAL FUNDING SUPPORT NECESSARY TO AFFORD INVESTIGATORS THE RESOURCES TO FOLLOW THROUGH WITH RESEARCH DISCOVERIES THAT WILL IMPROVE THE UNDERSTANDING OF AND TREATMENT FOR LUPUS. EACH SPRING, LUPUS RESEARCH ADVOCATES MEET WITH MEMBERS OF CONGRESS AND THEIR STAFF TO DESCRIBE THEIR PERSONAL LUPUS JOURNEY AND HOW THE DISEASE HAS AFFECTED THEIR LIFE, AND TO REQUEST SPECIFIC POLICIES THAT WILL MOVE LUPUS RESEARCH FORWARD. THE GOAL IS TO INCREASE AWARENESS OF LUPUS AND THE IMPACT IT HAS ON PEOPLE'S DAILY LIVES TO MEMBERS OF CONGRESS AND TO REQUEST THEIR SUPPORT FOR INCREASED FUNDING FOR LUPUS RESEARCH FROM FEDERAL PROGRAMS SUCH AS THE NIH AND CDMRP.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$571.1K
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)